Middle East Market Access: SFDA & EDE Compliance Consulting for EU Exporters.

Q: <strong>6. Which authority regulates pharmaceutical products and medical devices in the UAE?</strong>

The Emirates Drug Establishment (EDE) . Under Federal Decree-Law No. 38 of 2024, the EDE replaced MoHAP as the single federal authority for all pharmaceutical, biopharmaceutical, API, medical device, and Tatmeen serialization approvals in the UAE. (MoHAP retains oversight only over community pharmacy and practitioner licensing).

SFDA-Ready eCTD Dossiers, Climatic Zone IVb Validation, and Flawless Emirates Drug Establishment (EDE) Portal Onboarding.

Request a Dossier Gap Audit Explore Access Pathways

Outbound Regulatory Compliance Consulting for European Lifescience Innovators.

For European pharmaceutical, biotech, and medical device SMEs, the Middle East represents a highly lucrative expansion frontier. However, achieving compliant market entry requires an elite technical translator to navigate distinct, dual-track regulatory barriers:

The GCC Dossier Hurdle

eCTD Module 3 Misalignment:
Unaligned chemistry, manufacturing, and control (CMC) data formats trigger immediate portal rejections and costly dossier freezes.
Climatic Zone IVb Mandates:
Mandatory drug stability protocols must be meticulously proven and documented under strict heat and humidity parameters (30°C / 75% RH).

The Regional Compliance Maze

Sanctions & Export Control:
High-complexity environments (such as Syria and Iraq) require deep chemical dual-use (EU Reg 2021/821) and BAFA pre-clearance.
Consular Legalization Loop:
Multi-step embassy legalizations of Site Master Files (SMF) and GMP certificates in Berlin must be flawlessly coordinated.

CORE REGULATORY CONSULTING WORKFLOWS

eCTD Dossier Alignment

Key Deliverable:
📁 Submission-Ready eCTD Dossier Package

Pre-audit CMC data to preemptively resolve authority queries before submission.
Re-map Module 3 to match the precise portal e-services of the SFDA (Saudi) and EDE (UAE).
Leverage EMA approvals to trigger accelerated regional fast-track pathways.

Zone IVb Stability Validation

Key Deliverable:
🌡️ Climatic Zone IVb Compliance Report

Assess stability protocols against the strict 30°C / 75% RH GCC mandates.
Draft technical rationales and justification reports for any missing stability datasets.
Review packaging barriers to guarantee product integrity under extreme heat-zone conditions

SMF & Legalization Loop

Key Deliverable:
🏛️ Legalized Site Registration Package

Re-engineer Site Master Files (SMF)
to speak the exact language of Gulf GMP inspectorates.
Coordinate embassy legalizations of CPPs and GMP certificates in Berlin.
Establish local representation
by connecting your regulatory team with qualified regional QPPVs.

The “Dual-Hemisphere” Technical Authority

Levant Gate Pharma UG (haftungsbeschränkt) is powered by 14 years of elite cross-functional industry experience:

10 years rooted internally within German Biopharma Quality Assurance and strict GMP systemscombined with 4 years of specialized regional market access.

We speak the exact technical language of your Qualified Persons (QPs) and regulatory affairs teams, while natively navigating the e-portal architectures of Middle Eastern health authorities.

About US

Frequently Asked Questions on Regulatory Compliance Consulting

European CTD dossiers frequently encounter regulatory deficiency letters and months of re-submission delays due to regional divergence in eCTD formatting, localized portal requirements, and country-specific administrative mandates. We act as your inbound regulatory launchpad by conducting exhaustive pre-submission gap audits on European Drug Master Files (DMF) and technical dossiers. By mapping your CMC data directly to localized e-portal frameworks—such as the Saudi Food & Drug Authority (SFDA) and the Emirates Drug Establishment (EDE). We eliminate the standard 6–12 month trial-and-error review cycles caused by authority queries.

Standard European marketing authorizations typically rely on ICH Climatic Zone I or II long-term stability data (25°C / 60% RH). However, Gulf regulatory authorities mandate strict real-time and accelerated stability testing under Climatic Zone IVb (30°C / 75% RH). LGP evaluates your API and drug product degradation profiles, forced degradation studies, and container closure integrity against Zone IVb standards prior to submission, structuring supplemental stability protocols and commitment narratives that satisfy regional reviewers without triggering dossier rejection.

Regulatory submissions in the Middle East require multi-layered attestation of core administrative documents, including Certificates of Pharmaceutical Product (CPP), Certificates of Free Sale (FSC), and Site Master Files (SMF). Operating directly in Germany, LGP manages the end-to-end legalization workflow—from local health authority verification and state ministry certification to final consular legalization at Middle Eastern embassies (KSA, UAE, Qatar, Kuwait) in Berlin.

Exporting life science products into complex Levant markets requires strict adherence to European export controls. We execute mandatory technical pre-screening under EU Regulation 2021/821 to ensure chemical starting materials, APIs, and diagnostic Med-Tech are not flagged as dual-use precursors. For humanitarian supply to Syria or Iraq, we prepare BAFA derogation dossiers under EU CFSP guidelines (such as EU Council Reg 36/2012) and secure verified End-User Certificates (EUC) to guarantee total legal compliance for European principals.

No. Track 4 operates as a standalone, billable advisory service completely uncoupled from physical product trading, brokerage, or shipping timelines. European life science companies can retain Levant Gate Pharma UG on a fixed project fee or hourly advisory retainer to audit technical files, structure regional regulatory strategies, or manage serialization alignment (SFDA RSD, UAE Tatmeen) while maintaining total independence over their existing commercial distribution channels.

The Emirates Drug Establishment (EDE). Under Federal Decree-Law No. 38 of 2024, the EDE replaced MoHAP as the single federal authority for all pharmaceutical, biopharmaceutical, API, medical device, and Tatmeen serialization approvals in the UAE. (MoHAP retains oversight only over community pharmacy and practitioner licensing).

Secure Your Technical Consultation

Use the form below to outline your product portfolio (Standard Generics, Biosimilars, or Med-Tech hardware), and our lead consultant will contact your regulatory team within 24 business hours.